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Background
Impaired axonal transport may play an early, pivotal role
in a variety of neurodegenerative disorders, including
Parkinson’s disease (PD). For example, postmortem stu-
dies on PD patients show widespread axonal pathology
preceding the loss of cell bodies, animal models of
PD-linked mutations such as the R1441G LRRK2 muta-
tion exhibit decreased dopamine (DA) terminal fields
together with increased dystrophic processes and abnor-
mal axonal swellings, reduced axonal transport is also
seen with a-synuclein mutants, and the PD-like toxin,
MPP+, de-polymerizes microtubules leading to axon
fragmentation as well as directly inhibiting axon trans-
port in the isolated squid axoplasm. Thus, PD-linked
environmental and genetic factors support the hypoth-
esis that axon transport failure plays an early, critical
role in this disorder.
Methods
To discover how axon transport is disrupted in DA neu-
rons, we established a culture system in which DA neu-
rons are compartmentalized such that axons are on one
side leaving cell bodies and dendrites on the other. When
used with green fluorescent protein (GFP)-labeled DA
neurons derived from genetically engineered mice, DA
axons can be examined using live cell, real time imaging.
Therefore we used cellular, optical, and pharmacological
techniques to examine changes underlying toxin-mediated
DA axonal impairment.
Results
Our current studies show: (1) that the PD-mimetic MPP+
affects DA neuritic processes and microtubule tracks
12–18 h before cell bodies appear altered; (2) MPP+ halts
mitochondrial trafficking in DA but not non-DA axons
within 30 min; (3) remaining motile mitochondria exhibit
decreased anterograde movement but increased retrograde
trafficking; (4) MPP+ effects are specific for mitochondria,
as synaptophysin-tagged vesicles and other detectable
moving particles continue normal movements in either
direction; (5) decreased mitochondrial trafficking is
accompanied by a loss of ΔΨm; (6) loss of mitochondrial
movement is not associated with ATP loss but rather
redox changes; (7) DA mitochondria are smaller and
slower than non-DA organelles, suggesting cell type-speci-
fic differences exist for axonal mitochondria; and (8) the
Wallerian degeneration slow fusion protein (WldS) can
rescue the effect of MPP+
Conclusions
These studies confirm and dramatically extend the notion
that axonal transport impairment plays a significant role
in PD. Moreover, these findings underscore the necessity
of developing therapeutics aimed at axons as well as cell
bodies so as to preserve circuitry and function.
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